Leukemia

Older patients with B-cell malignancies diagnosed with COVID-19 had a substantially higher risk for death than their counterparts aged 60 years or younger, according to study results published in JCO Oncology Practice.

Younger Hispanic/Latinx patients face many barriers that may limit timely access to chimeric antigen receptor T-cell therapy trials for relapsed or refractory B-cell acute lymphoblastic leukemia, according to retrospective study results.

A chimeric antigen receptor T-cell therapy induced high response rates across a range of B-cell malignancies, according to phase 1 study results presented at ASH Annual Meeting and Exposition.

Fully vaccinated patients with cancer who developed breakthrough COVID-19 infections appeared at high risk for hospitalization and death, according to study results published in Annals of Oncology.

The FDA granted fast track designation to CYNK-001 for the treatment of adults with relapsed or refractory acute myeloid leukemia.

In the last two decades, the approval of multiple tyrosine kinase inhibitors for chronic myeloid leukemia has vastly improved the treatment landscape for patients.

Patients with blood cancer appeared at greater risk for severe and life-threatening COVID-19 illness than healthy individuals and did not always achieve optimal protection from vaccination, according to a registry-based study in Blood.

The FDA granted orphan drug designation to NKX101 for treatment of acute myeloid leukemia.

Early clinical trials for the first chimeric antigen receptor T-cell therapies mandated recipients receive rigorous post-treatment monitoring, often requiring inpatient admittance lasting anywhere from 2 to 4 weeks.

Healio provided comprehensive coverage of this year’s ASH Annual Meeting and Exposition.